Drug
Lyl845
Lyl845: highest development phase Phase 1, developed by Lyell Immunopharma. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Lyell Immunopharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| LYL845 NCT05573035 | Phase 1 | Melanoma |
Latest
No recent events.
Follow Lyl845 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.